177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry Abstract #2880

Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.
Aim(s): The aim was to describe the characteristics of patients and advanced somatostatin receptor–positive neuroendocrine tumours (TNE) treated with 177Lu-DOTATATE (PRRT) and to evaluate the efficacy and safety.
Materials and methods: The data come from the SEPTRALU national study in which a multidisciplinary team of 18 centers participate. Survival was evaluated using the Kaplan-Meier method and Cox proportional risk regression. Toxicity was recorded according to CTCAEv3.0 criteria.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Alberto Carmona-Bayonas

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2292 PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) – The Rotterdam Cohort
Introduction: PRRT with 177Lu-DOTATATE (LuTate) is effective in patients with metastatic or inoperable GEP-NETs.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Wouter van der Zwan
#1128 FDG PET as a Prognostic Factor in Pancreatic Neuroendocrine Tumors (P-NET) After Peptide Receptor Radionuclide Therapy with 177Lu-dotatate (Lu-PRRT).
Introduction: The best-known altered metabolism in cancer is an increased glycolysis. FDG-PET allow us to obtain in vivo imaging of this metabolic abnormality which is an hallmark of tumor aggressiveness.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini
#817 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Introduction: There are a few case reports on surgery after peptide receptor radionuclide therapy (PRRT).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Surgical treatment
Presenting Author: Emilio Bertani
Authors: Bertani E, Chiappa A, Fazio N, Grana C, ...
#2897 Comparison of 68Ga-DOTATATE PET/CT for Assessment of Response to Peptide Receptor Radionuclide Therapy after 2 and 4 Cycles of 177Lu-DOTATATE: Preliminary Single Academic Center Experience
Introduction: Peptide receptor radionuclide therapy (PRRT) usually leads to stable rather than decreased lesion size in neuroendocrine tumors (NETs), therefore RECIST criteria are not used to assess early response to treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Hong Song
Authors: Song H, Kunz P, Fisher G, Franc B, ...
#1644 Pitfalls in the Response Evaluation after Peptide Receptor Radionuclide Therapy with [177Lu-DOTA0,Tyr3]Octreotate
Introduction: PPRT with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic GEPNETs
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Tessa Brabander